Meldonium and Semax Interaction: Monitor | Peptide Database

Meldonium is increasingly used in the performance enhancement community as an adjunctive agent to protect the heart during anabolic steroid cycles. Supraphysiological androgen use is associated with left ventricular hypertrophy, impaired diastolic function, reduced ejection fraction, and accelerated atherosclerosis. Meldonium's ability to optimize cardiac energy metabolism and reduce toxic lipid intermediates may mitigate some of these effects, though direct clinical evidence in this specific context is limited to anecdotal and observational data. By shifting fuel utilization from fatty acids toward glucose, meldonium may improve aerobic efficiency under submaximal exercise conditions. Athletes in Eastern European countries have used meldonium for decades to support training capacity and recovery. The metabolic shift may spare glycogen during prolonged activity and reduce post-exercise oxidative stress. This use drove WADA's decision to ban the substance. In Baltic states and Russia, meldonium is an approved prescription drug for the treatment of stable angina pectoris and chronic ischemic heart disease. Clinical trials conducted primarily in Latvia and Russia have demonstrated reductions in angina frequency, improved exercise tolerance on treadmill testing, and reduced nitroglycerin consumption when meldonium is added to standard antianginal therapy. Meldonium has been investigated as an adjunctive therapy in chronic heart failure, where impaired cardiac energy metabolism contributes to disease progression. Small trials have reported improvements in exercise capacity and quality-of-life scores when meldonium was added to standard heart failure regimens. Larger-scale, Western-standard randomized controlled trials are lacking. The drug is prescribed in some Eastern European countries for acute and chronic cerebrovascular insufficiency. Its vasodilatory effects via nitric oxide stimulation and metabolic optimization may offer neuroprotective benefits during ischemic events. Evidence is primarily from non-Western clinical trials.

Join others researching IllumiNeuro Protocol — share findings, ask questions, and learn from real experiences IllumiNeuro is a cognitive enhancement peptide blend combining four nootropic peptides: PE-22-28 (neuritogenic), Pinealon (pineal bioregulator), NA-Semax Amidate (neuroprotective/cognitive), and NA-Selank Amidate (anxiolytic/cognitive). The standard formulation contains 48mg total (PE-22-28 10mg + Pinealon 10mg + NA-Semax 20mg + NA-Selank 8mg). This blend targets multiple neurological pathways for comprehensive cognitive support, though no clinical studies exist on this specific four-peptide combination. Each peptide contributes distinct neurological mechanisms: PE-22-28 promotes neurite outgrowth and neural connectivity through sphingosine-1-phosphate receptor modulation; Pinealon is a bioregulator that supports pineal gland function and circadian regulation; NA-Semax Amidate provides BDNF upregulation and neuroprotection; NA-Selank Amidate offers anxiolytic effects through GABA modulation and immune-neuroendocrine regulation. Together, they theoretically address cognitive enhancement, neuroprotection, mood support, and neural regeneration.